The role of cytochrome P-450 in the myogenic response of isolated, perfused renal arcuate arteries of dogs to elevations in transmural pressure was examined. The phospholipase A2 inhibitor oleyloxyethylphosphorylcholine (1 and 10 ,uM) inhibited the greater than threefold increase in active wall tension in these arteries after an elevation in perfusion pressure from 80 to 160 mm Hg. Inhibition of cyclooxygenase activity with indomethacin (1 or 10 ,uM) had no effect on this response. The cytochrome P-450 inhibitors ketoconazole (10 and 100 ,uM) and ,f-diethyl-aminoethyldiphenylpropylacetate (SKF 525A, 10 and 100 ,uM) also inhibited the myogenic response. At a pressure of 160 mm Hg, SKF 525A (10 jiM) and ketoconazole (100 ,uM) reduced active wall tension in renal arteries by approximately 70%. Partial inhibition of the myogenic response was obtained after perfusion of the vessels with mechanism-based inhibitors of P-450, 1-aminobenzotriazole (75 uM) and 12-hydroxy-16-heptadecynoic acid (20 ,uM). The thromboxane receptor antagonist SQ 29,548 (1 or 10 JIM) had no effect on the pressure-induced increase in active wall tension in renal arteries. Arachidonic acid (50 ,uM) constricted isolated perfused renal arteries and potentiated the myogenic response in the presence of indomethacin. This response was completely reversed by ketoconazole (100 ,uM) or SKF 525A (100 ,uM). Microsomes (1 mg/ml) prepared from small renal arteries (200-500 ,um) and incubated with [1-14C]arachidonic acid (0.5 ,uCi, 50 ,uM) produced a metabolite that coeluted with 20-hydroxyeicosatetraenoic acid (20-HETE) during reversed-phase high-performance liquid chromatography. The formation of this product was inhibited by both ketoconazole and SKF 525A at concentrations of 10 and 100 ,uM. These results are consistent with the involvement of the vasoconstrictor 20-HETE and other cytochrome P-450 metabolites of endogenous fatty acids in the myogenic response. (Circulation Research 1991;68:1154-1163 endothelium,45 and in cerebral arteries it is associated with the release of a factor that constricts and depolarizes vascular smooth muscle.5 These observations have led to the suggestion that the release of an endothelium-dependent constrictor factor mediates the myogenic response.5,6 Arachidonic acid can be metabolized by cyclooxygenase, lipoxygenase, and cytochrome P-450-dependent pathways.7 A variety of eicosanoids are produced by vascular tissues including prostaglandins E2, D2, and F2a; thromboxane B2; prostacyclin; 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids (5-, 11-, 12-, and 15-HETEs); 14,15-epoxyeicosatrienoic acid (14, and 14, .7-12 Recent findings that indomethacin6 and nordihydroguaiaretic acid13 block the stretch-and pressure-evoked constriction of cerebral arteries suggest that a metabolite of arachidonic acid may be involved in this response. These observations are also consistent with previous results indicating by guest on April 3, 2017
The role of cytochrome P-450 in the myogenic response of isolated, perfused renal arcuate arteries of dogs to elevations in transmural pressure was examined. The phospholipase A2 inhibitor oleyloxyethylphosphorylcholine (1 and 10 ,uM) inhibited the greater than threefold increase in active wall tension in these arteries after an elevation in perfusion pressure from 80 to 160 mm Hg. Inhibition of cyclooxygenase activity with indomethacin (1 or 10 ,uM) had no effect on this response. The cytochrome P-450 inhibitors ketoconazole (10 and 100 ,uM) and ,f-diethyl-aminoethyldiphenylpropylacetate (SKF 525A, 10 and 100 ,uM) also inhibited the myogenic response. At a pressure of 160 mm Hg, SKF 525A (10 jiM) and ketoconazole (100 ,uM) reduced active wall tension in renal arteries by approximately 70%. Partial inhibition of the myogenic response was obtained after perfusion of the vessels with mechanism-based inhibitors of P-450, 1-aminobenzotriazole (75 uM) and 12-hydroxy-16-heptadecynoic acid (20 ,uM) . The thromboxane receptor antagonist SQ 29,548 (1 or 10 JIM) had no effect on the pressure-induced increase in active wall tension in renal arteries. Arachidonic acid (50 ,uM) constricted isolated perfused renal arteries and potentiated the myogenic response in the presence of indomethacin. This response was completely reversed by ketoconazole (100 ,uM) or SKF 525A (100 ,uM). Microsomes (1 mg/ml) prepared from small renal arteries (200-500 ,um) and incubated with [1-14C] arachidonic acid (0.5 ,uCi, 50 ,uM) produced a metabolite that coeluted with 20-hydroxyeicosatetraenoic acid (20-HETE) during reversed-phase high-performance liquid chromatography. The formation of this product was inhibited by both ketoconazole and SKF 525A at concentrations of 10 and 100 ,uM. These results are consistent with the involvement of the vasoconstrictor 20-HETE and other cytochrome P-450 metabolites of endogenous fatty acids in the myogenic response. (Circulation Research 1991; 68:1154 -1163 I solated perfused arteries obtained from the renal, cerebral, and skeletal muscle vascular beds all exhibit a myogenic response to increases in transmural pressure.1-3 This response is involved in the regulation of blood flow in most vascular beds. Recent studies of the mechanism of the myogenic response indicate that it is dependent on an intact endothelium,45 and in cerebral arteries it is associated with the release of a factor that constricts and depolarizes vascular smooth muscle.5 These observations have led to the suggestion that the release of an endothelium-dependent constrictor factor mediates the myogenic response. 5, 6 Arachidonic acid can be metabolized by cyclooxygenase, lipoxygenase, and cytochrome P-450-dependent pathways.7 A variety of eicosanoids are produced by vascular tissues including prostaglandins E2, D2, and F2a; thromboxane B2; prostacyclin; 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids (5-, 11-, 12-, and 15-HETEs); 14,15-epoxyeicosatrienoic acid (14, ; and 14,15-dihydroxyeicosatrienoic acid (14, The effects of ketoconazole and SKF 525A (10 and 100 ,LM) on the metabolism of arachidonic acid by renal artery microsomes were studied. Microsomes were prepared from 5 g of small renal arteries (100-400 ,um) that were microdissected from the kidneys of 17 dogs. The vessels were kept in ice-cold PSS during the dissection and later blotted dry, frozen in liquid nitrogen, and stored at -80°C until the microsomes were prepared. The frozen vascular tissue was powdered in liquid nitrogen by using a mortar and pestle and homogenized in a 10 mM potassium phosphate buffer (pH 7.7) containing 250 mM sucrose, 1 mM EDTA, and 10 mM MgCl2. The homogenate was centrifuged for 10 minutes at 3,500g, 30 minutes at 9,OOOg, and 60 minutes at 100,OOOg to obtain the microsomal pellet. The microsomes were resuspended in a 100 mM potassium phosphate buffer (pH 7.4) and used immediately.
Microsomes (1 mg/ml) were incubated for 60 minutes at 37°C with [1-14C] arachidonic acid (0.5
,uCi/ml, 50 ,uM) in 1 ml of a 100 mM potassium phosphate buffer (pH 7.4) containing 5 mM MgC12, 1 mM EDTA, 1 mM NADPH, and an NADPH-regenerating system consisting of 10 mM isocitrate and isocitrate dehydrogenase (0.4 units/ml). The reaction was terminated by acidification to pH 4 using 1 M HCl followed by extraction with ethyl acetate and subsequent evaporation of the solvent. The metabolites were separated using a 2 mm x 25 cm C18 reversed-phase analytical high-performance liquid chromatography column and a linear elution gradient from acetonitrile:water:acetic acid (50/50/0. Figure 2A . During the control period, vascular diameter decreased by 4 .4±1.6% when pressure was elevated from 80 to 160 mm Hg. The addition of indomethacin (1 and 10 ,M) to the bath had little effect on the pressure-diameter relation (Figure 2A) or the increase in active wall tension ( Figure 2B ) produced by an elevation in transmural pressure. The only significant effect seen in these experiments was a slight potentiation (23%) of active tension at a pressure of 160 mm Hg in the vessels treated with 10 ,uM indomethacin in the bath. The effects of SKF 525A, an inhibitor of cytochrome P-450, on the myogenic response are presented in Figure 3 . During the control period, the diameter of this group of vessels decreased 3+±0.6% when pressure was increased from 80 to 160 mm Hg ( Figure 3A) . After the addition of 10 uM SKF 525A to the perfusate, the diameter of these vessels increased significantly by 9+1% in response to the same increase in transmural pressure. The addition of SKF 525A to the lumen of the vessel also attenuated the increase in active tension produced in response to an elevation in transmural pressure; at a pressure of 160 mm Hg, active tension in these vessels was reduced by 49%. The vascular response was greater when SKF 525A was added to the bath ( Figure 3B ). SKF 525A at concentrations of 10 and 100 ,uM in the bath produced marked vasodilation ( Figure 3A) , and removal of calcium from the perfusate and the bath had no additional effect on the pressure-diameter relation. The addition of either 10 or 100 ,uM SKF 525A to the bath completely blocked the increase in active wall tension in response to an elevation in transmural pressure and reduced active tension in these vessels at a pressure of 160 mm Hg by 69% and 77%, respectively. Similar results were obtained using ketoconazole, a structurally dissimilar inhibitor of cytochrome P-450. The addition of 100 ,uM ketoconazole to the perfusate significantly increased the diameter of the vessels ( Figure 4A ) and reduced the development of active tension by 32% at a pressure of 160 mm Hg ( Figure 4B ). When added to the bath, ketoconazole (10 ttM) had no significant effect on the pressure- Figure 5 . Exposure of the lumen of the vessels to ABT or 12-HHDYA for 30 minutes significantly increased vascular diameter at pressures of 120 and 160 mm Hg ( Figure SA) Figure  6 . SQ 29,548 had no effect on the pressure-diameter relation ( Figure 6A ), nor did it alter the increment in active wall tension in these arteries in response to an elevation in transmural pressure ( Figure 6B ).
Effect ofArachidonic Acid on the Myogenic Response
To determine whether isolated, perfused renal arcuate arteries can produce vasoactive metabolites from arachidonic acid, the effects of arachidonic acid ( Figure 7A ) and completely blocked the increment in active wall tension produced by an elevation in transmural pressure ( Figure 7B ).
Metabolism of Arachidonic Acid by Renal Artery Microsomes
The results of the experiments to study the effects of ketoconazole and SKF 525A on the metabolism of arachidonic acid by microsomes prepared from small renal arteries are presented in Figures 8 and 9 . Microsomes prepared from renal arteries produced three products when incubated with arachidonic acid (retention time 30 minutes) that had retention times of 3, 12.5, and 39 minutes (Figure 8 ). The polar metabolite (3 minutes) elutes in the region that the cyclooxygenase products prostaglandin E2 and 6-ketoprostaglandin F,, normally elute. The identity of the nonpolar product with a retention time of 39 minutes is unknown, but the production of this compound was not NADPH dependent or inhibited by cyclooxygenase or cytochrome P-450 inhibitors (data not shown). The remaining metabolite with a retention time of 12.5 minutes coelutes with a 20-HETE standard. However, the identity of this product needs to be confirmed by gas chromatographymass spectroscopy once sufficient amounts can be obtained because other cytochrome P-450 products such as 19 Pressure (mmHg) FIGURE 7. Effect of arachidonic acid (AA, 50 pM) in the presence and absence of indomethacin (Indo, 10 pM), and indomethacin (10 p.M) plus ketoconazole (Keto, 100 dM; n=3) or SKF 525A (SKF, 100 gl; n=4) on the pressurediameter (panel A) and pressure-active tension (panel B) relations of dog renal arcuate arteries at different levels of transmural pressure. Mean ±1 SEM from seven vessels is presented. The response to both cytochrome P-450 inhibitors, ketoconazole and SKF 525A, was similar; therefore, the data from these two groups were combined and presented together. The control diameters of the vessels averaged 305±25 ,um at a pressure of80 mm Hg. *Significant difference from the value measured at 80 mm Hg within a group. tSignificant difference from the control value measured at the same transmural pressure. tSignificant difference from the values obtained before administration of ketoconazole or SKF 525A in vessels pretreated with arachidonic acid and indomethacin.
on the myogenic response were studied in the presence and absence of cyclooxygenase and cytochrome P-450 inhibitors (Figure 7 ). Increasing substrate availability by adding arachidonic acid (50 ,uM) to the bath significantly reduced the diameter of the vessels at all pressures studied ( Figure 7A ). The vasoconstrictor response to arachidonic acid was potentiated by indomethacin (10 ,uM) , and the increase in active vascular tone in response to elevations in perfusion pressure was significantly enhanced ( Figure 7B ). The addition of 100 ,uM ketoconazole (n=3) or 100 guM SKF 525A (n=4) to the bath had similar effects on the vessels treated with arachidonic acid and indomethacin. They both increased vascular diameter In summary, the pressure-induced myogenic response of dog renal arcuate arteries could be blocked by an inhibitor of phospholipase A2 and several cytochrome P-450 inhibitors. Arachidonic acid constricted renal arteries in the presence of a cyclooxygenase inhibitor and potentiated the myogenic response. This effect was reversed by inhibitors of cytochrome P-450. Microsomes prepared from small renal arteries produced a compound that coelutes with 20-HETE during reversed-phase high-performance liquid chromatography. The production of this metabolite of arachidonic acid was blocked by cytochrome P-450 inhibitors at concentrations similar to those that attenuated the myogenic response of isolated perfused renal arteries. These results suggest the involvement of a cytochrome P-450 metabolite of arachidonic acid or other endogenous fatty acids in the pressure-induced myogenic response of small renal arteries.
